Abstract IA002: Genomic and epigenomic regulation during prostate cancer progression

Abstract

Abstract Prostate cancer (PCa) development and progression are controlled by aberrant expression, mutation, and function of essential transcriptional factors and epigenetic modifiers. Over the years, our work has delineated the molecular mechanisms by which androgen receptor (AR) and Polycomb Repressive Complex 2 (PRC2) protein EZH2 regulate PCa progression in concert with other key transcriptional factors such as TMPRSS2-ERG and FOXA1. We recently found that HOXB13, a homeodomain transcription factor primarily known as a pioneering factor of AR, plays an AR-independent role in inhibiting cancer metabolism and tumor metastasis. An important function that is mediated by its interaction with the HDAC3-NCoR corepressor complex, which is disrupted by the PCa risk-associated HOXB13 G84E mutation. On the other hand, we characterize the unique roles of PALI1, a newly identified PRC2-accessory protein, in mediating molecular crosstalk between PRC2 and G9A proteins to catalyze dual H3K27 and H3K9 methylation at target loci. Thus, PALI1 enforces strong repression of differentiation genes, rendering cell stemness and cancer progression. Our findings laid the foundations for the development of several new therapeutic strategies for the treatment of advanced PCa. Citation Format: Jindan Yu. Genomic and epigenomic regulation during prostate cancer progression [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr IA002.